Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Complete pathological response after chemotherapy or immune checkpoint inhibitors in deficient MMR metastatic colorectal cancer: Results of a retrospective multicenter study.
Marolleau P, Tougeron D, Allignet B, Cohen R, Sefrioui D, Gallet B, Dumont F, Guimbaud R, Alouani E, Passot G, Desolneux G, Ghiringhelli F, Marchal F, Mourthadhoi F, Coriat R, Desgrippes R, Locher C, Goujon G, Des Guetz G, Aparicio T, Paubelle E, Dupré A, de la Fouchardière C. Marolleau P, et al. Among authors: alouani e. Int J Cancer. 2023 Oct 1;153(7):1376-1385. doi: 10.1002/ijc.34636. Epub 2023 Jul 5. Int J Cancer. 2023. PMID: 37403609
Efficacy of immunotherapy in mismatch repair-deficient advanced colorectal cancer in routine clinical practice. An AGEO study.
Alouani E, Mercier M, Flecchia C, Auclin E, Hollebecque A, Mazard T, Turpin A, Pernot S, Cohen R, Dutherage M, Kim S, Sclafani F, Ben-Abdelghani M, Herve C, Aparicio T, De La Fouchardière C, Perkins G, Hautefeuille V, Jaffrelot M, Gallois C, Bongard V, Tougeron D, Taïeb J, Guimbaud R. Alouani E, et al. ESMO Open. 2023 Jun;8(3):101574. doi: 10.1016/j.esmoop.2023.101574. Epub 2023 May 25. ESMO Open. 2023. PMID: 37244250 Free PMC article.
Immunosuppressant mycophenolate mofetil for patients with steroid-refractory immune-related hepatitis induced by checkpoint inhibitors in oncology.
Alouani E, Laparra A, Perret A, Sakkal M, Messayke S, Danlos FX, Ouali K, Hollebecque A, Even C, Ammari S, Baldini C, Champiat S, Besse B, Robert C, Guettier C, Samuel D, Lambotte O, De Martin E, Michot JM. Alouani E, et al. Eur J Cancer. 2023 Nov;193:113313. doi: 10.1016/j.ejca.2023.113313. Epub 2023 Aug 26. Eur J Cancer. 2023. PMID: 37748398
Profile and outcome of cancer patients enrolled in contemporary phase I trials.
Alouani E, Gazzah A, Mercier S, Bahleda R, Hollebecque A, Michot JM, Baldini C, Ammari S, Champiat S, Marabelle A, Postel-Vinay S, Ribrag V, Loriot Y, Aix SP, Mahjoubi L. Alouani E, et al. Eur J Cancer. 2023 Jul;188:1-7. doi: 10.1016/j.ejca.2023.04.006. Epub 2023 Apr 20. Eur J Cancer. 2023. PMID: 37178645 Clinical Trial.
Is there a role for locoregional treatment of the primary tumor in de novo metastatic breast cancer in the era of tailored therapies?: Evidences, unresolved questions and a practical algorithm.
Pons-Tostivint E, Alouani E, Kirova Y, Dalenc F, Vaysse C. Pons-Tostivint E, et al. Among authors: alouani e. Crit Rev Oncol Hematol. 2021 Jan;157:103146. doi: 10.1016/j.critrevonc.2020.103146. Epub 2020 Nov 12. Crit Rev Oncol Hematol. 2021. PMID: 33227574 Review.
A multicenter study evaluating efficacy of immune checkpoint inhibitors in advanced non-colorectal digestive cancers with microsatellite instability.
Moreau M, Alouani E, Flecchia C, Falcoz A, Gallois C, Auclin E, André T, Cohen R, Hollebecque A, Turpin A, Pernot S, Masson T, Di Fiore F, Dutherge M, Mazard T, Hautefeuille V, Van Laethem JL, De la Fouchardière C, Perkins G, Ben-Abdelghani M, Sclafani F, Aparicio T, Kim S, Vernerey D, Taieb J, Guimbaud R, Tougeron D. Moreau M, et al. Among authors: alouani e. Eur J Cancer. 2024 May;202:114033. doi: 10.1016/j.ejca.2024.114033. Epub 2024 Mar 21. Eur J Cancer. 2024. PMID: 38537314 Free article. Clinical Trial.
16 results